产品名称
钇, wire reel, 0.2m, diameter 1.0mm, 99.9%
InChI
1S/Y
SMILES string
[Y]
InChI key
VWQVUPCCIRVNHF-UHFFFAOYSA-N
assay
≥99.9%
form
wire
manufacturer/tradename
Goodfellow 863-941-56
resistivity
57 μΩ-cm, 20°C
bp
3338 °C (lit.)
mp
1522 °C (lit.)
density
4.469 g/mL at 25 °C (lit.)
正在寻找类似产品? 访问 产品对比指南
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
存储类别
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Hojjat Ahmadzadehfar et al.
Seminars in nuclear medicine, 40(2), 105-121 (2010-02-02)
Radioembolization (RE), also termed selective internal radiation therapy (SIRT), has been gradually introduced to the clinical arsenal of cytoreductive modalities in recent years. There is growing evidence for efficiency in liver tumors of various entities, with the most prominent ones
Dan Li et al.
Journal of nanoscience and nanotechnology, 14(6), 4207-4213 (2014-04-18)
YF3:Er3+ hollow nanofibers were successfully fabricated via fluorination of the relevant Y2O3:Er3+ hollow nanofibers which were obtained by calcining the electrospun PVP/[Y(NO3)3 + Er(NO3)3] composite nanofibers. The morphology and properties of the products were investigated in detail by X-ray diffraction
Yukiko Ishihara et al.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 31(8), 781-785 (2015-08-11)
With a view to enhance the sensitivity of analytical instruments used in the measurement of trace elements contained in a single cell, we have now equipped the previously reported micro-droplet injection system (M-DIS) with a desolvation system. This modified M-DIS
Aki Aoyama et al.
Molecular cancer therapeutics, 13(12), 2978-2990 (2014-10-15)
Tivantinib (ARQ197) was first reported as a highly selective inhibitor of c-MET and is currently being investigated in a phase III clinical trial. However, as recently reported by us and another group, tivantinib showed cytotoxic activity independent of cellular c-MET
Ryan Hickey et al.
International journal of radiation oncology, biology, physics, 88(5), 1025-1031 (2014-03-26)
Radiosensitizing chemotherapy improves the outcomes in comparison with radiation alone for gastrointestinal cancers. The delivery of radiation therapy with yttrium90 ((90)Y) radioembolization, in combination with the radiosensitizing chemotherapeutic agent capecitabine, provides the opportunity to enhance the effects of radiation on
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持